Primary Site >> Biliary tract Cancer
Gene >> BRAF
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Ref: Stimulation of alpha2-adrenergic receptor inhibits cholangiocarcinoma growth through modulation of Raf-1 and B-Raf activities. PMID: 12029618 |
Ref: Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma. PMID: 12692057 |
Ref: Tauroursodeoxycholate inhibits human cholangiocarcinoma growth via Ca2+-, PKC-, and MAPK-dependent pathways. PMID: 14701718 Ref: The V599E BRAF mutation is uncommon in biliary tract cancers. PMID: 15181454 Ref: Mutational analysis of BRAF in gallbladder carcinomas in association with K-ras and p53 mutations and microsatellite instability. PMID: 15221372 |
Ref: Molecular testing for microsatellite instability and DNA mismatch repair defects in hereditary and sporadic colorectal cancers--ready for prime time? PMID: 17962726 |
Ref: Molecular analysis of PIK3CA, BRAF, and RAS oncogenes in periampullary and ampullary adenomas and carcinomas. PMID: 19440799 |
Ref: Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial. PMID: 19935794 |
Ref: KRAS and PIK3CA but not BRAF genes are frequently mutated in Chinese cholangiocarcinoma patients. PMID: 21051183 Ref: Mutations in the RAS/RAF/MAP kinase pathway commonly occur in gallbladder adenomas but are uncommon in gallbladder adenocarcinomas. PMID: 21307665 |
Ref: Intraductal tubulopapillary neoplasm of the bile duct: potential origin from peribiliary cysts. PMID: 21813159 Ref: Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors. PMID: 22178589 Ref: Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. PMID: 22180306 |
Ref: Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. PMID: 23295441 Ref: Molecular profiling of cholangiocarcinoma shows potential for targeted therapy treatment decisions. PMID: 23391413 Ref: The frequency of KRAS and BRAF mutations in intrahepatic cholangiocarcinomas and their correlation with clinical outcome. PMID: 24139215 Ref: A phase II trial of gemcitabine, irinotecan and panitumumab in advanced cholangiocarcinoma. PMID: 24146220 |
Ref: Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma. PMID: 24122810 Ref: High throughput molecular profiling reveals differential mutation patterns in intrahepatic cholangiocarcinomas arising in chronic advanced liver diseases. PMID: 24186137 Ref: Epidermal growth factor receptor signaling pathway is frequently altered in ampullary carcinoma at protein and genetic levels. PMID: 24186143 Ref: BRAF V600E-specific immunohistochemistry reveals low mutation rates in biliary tract cancer and restriction to intrahepatic cholangiocarcinoma. PMID: 24309328 Ref: Clinicopathological and prognostic significances of EGFR, KRAS and BRAF mutations in biliary tract carcinomas in Taiwan. PMID: 24372748 Ref: Genomic profiling of intrahepatic cholangiocarcinoma: refining prognosis and identifying therapeutic targets. PMID: 24889489 Ref: Dramatic response to dabrafenib and trametinib combination in a BRAF V600E-mutated cholangiocarcinoma: implementation of a molecular tumour board and next-generation sequencing for personalized medicine. PMID: 25435907 Ref: Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications. PMID: 25536104 |
Ref: Massive parallel sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma. PMID: 25608663 Ref: BRAF V600E mutational status in bile duct adenomas and hamartomas. PMID: 25704541 Ref: Pathogenesis of cholangiocarcinoma: From genetics to signalling pathways. PMID: 25966424 Ref: Intraductal tubulopapillary neoplasms of the bile ducts: clinicopathologic, immunohistochemical, and molecular analysis of 20 cases. PMID: 26111977 Ref: Molecular profiling of intrahepatic and extrahepatic cholangiocarcinoma using next generation sequencing. PMID: 26189129 |
Ref: Molecular Pathogenesis and Targeted Therapies for Intrahepatic Cholangiocarcinoma. PMID: 26405193 Ref: Intraductal tubulopapillary neoplasm of the bile duct: A case report and review of the published work. PMID: 26459784 Ref: Comprehensive genomic profiling of extrahepatic cholangiocarcinoma reveals a long tail of therapeutic targets. PMID: 26500333 Ref: Cholangiocarcinoma with intraductal tubular growth pattern versus intraductal papillary growth pattern. PMID: 26769137 Ref: Genomics of gallbladder cancer: the case for biomarker-driven clinical trial design. PMID: 26857926 Ref: The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targets. PMID: 27102149 Ref: Molecular profiling of biliary tract cancer: a target rich disease. PMID: 27747093 Ref: Molecular characteristics of biliary tract cancer. PMID: 27823638 Ref: KRAS Mutation as a Potential Prognostic Biomarker of Biliary Tract Cancers. PMID: 28008299 Ref: Impressive response to dual BRAF and MEK inhibition in patients with BRAF mutant intrahepatic cholangiocarcinoma-2 case reports and a brief review. PMID: 28078132 |
Ref: BRAF V600E mutation in biliary proliferations associated with alpha1 -antitrypsin deficiency. PMID: 27627051 Ref: Mutation analysis and copy number changes of KRAS and BRAF genes in Taiwanese cases of biliary tract cholangiocarcinoma. PMID: 27745798 Ref: BRAF(V600) mutations in solid tumors, other than metastatic melanoma and papillary thyroid cancer, or multiple myeloma: a screening study. PMID: 28255242 Ref: Combined dabrafenib and trametinib treatment in a case of chemotherapy-refractory extrahepatic BRAF V600E mutant cholangiocarcinoma: dramatic clinical and radiological response with a confusing synchronic new liver lesion. PMID: 28480077 Ref: Adenosquamous gallbladder carcinoma: Multigene hotspot mutational profiling reveals a monoclonal origin of the two components. PMID: 28698100 Ref: Systemic and Adjuvant Therapies for Intrahepatic Cholangiocarcinoma. PMID: 28975832 |
Ref: Phase I dose-escalation study of copanlisib in combination with gemcitabine or cisplatin plus gemcitabine in patients with advanced cancer. PMID: 29348486 Ref: Novel targeted therapy strategies for biliary tract cancers and hepatocellular carcinoma. PMID: 29460642 Ref: Hybrid Capture-Based Tumor Sequencing and Copy Number Analysis to Confirm Origin of Metachronous Metastases in BRCA1-Mutant Cholangiocarcinoma Harboring a Novel YWHAZ-BRAF Fusion. PMID: 29622700 Ref: [ASCO- and ESMO-update 2017 - highlights of the 53. meeting of the American Society of Clinical Oncology/ASCO 2017 and European Society for Medical Oncology/ESMO congress 2017]. PMID: 29642252 Ref: Mucinous intrahepatic cholangiocarcinoma: a distinct variant. PMID: 29698701 Ref: Phase 1b investigation of the MEK inhibitor binimetinib in patients with advanced or metastatic biliary tract cancer. PMID: 29785570 Ref: New developments in systemic therapy for advanced biliary tract cancer. PMID: 29893894 |